Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 75 of 111 entries
View as:

A Study to Evaluate the Effect of Volanesorsen on Cardiac Repolarization Conducted in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02910635 Org: User:
Start: 09/19/16 End: 12/20/16 Due: 12/20/17

Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations

Phase: N/A Priority: Normal
NCT ID: NCT01041222 Org: User:
Start: 01/31/10 End: 01/31/12 Due: 01/31/13

A Study to Assess the Safety, Tolerability, and Efficacy of ION-827359 in Participants With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis (CB)

Phase: N/A Priority: Normal
NCT ID: NCT04441788 Org: User:
Start: 12/22/20 End: 08/09/21 Due: 08/09/22

A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection Fraction

Phase: N/A Priority: Normal
NCT ID: NCT04836182 Org: User:
Start: 06/08/21 End: 01/11/23 Due: 01/11/24

ISIS 2302-CS27, A 6-Week, Placebo-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis.

Phase: N/A Priority: Normal
NCT ID: NCT00063830 Org: User:
Start: 04/03/03 End: 10/11/04 Due: 10/11/05

An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary Angioedema

Phase: N/A Priority: Normal
NCT ID: NCT04307381 Org: User:
Start: 04/01/20 End: 01/24/25 Due: 01/24/26

A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood Pressure

Phase: N/A Priority: Normal
NCT ID: NCT04714320 Org: User:
Start: 04/28/21 End: 10/03/22 Due: 10/03/23

A Study to Assess the Clinical Efficacy of Donidalorsen (Also Known as IONIS-PKK-LRx and ISIS 721744) in Participants With Hereditary Angioedema

Phase: N/A Priority: Normal
NCT ID: NCT04030598 Org: User:
Start: 01/07/20 End: 03/01/21 Due: 03/01/22

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS ANGPTL3-LRx in Healthy Volunteers With Elevated Triglycerides and Participants With Familial Hypercholesterolemia

Phase: N/A Priority: Normal
NCT ID: NCT02709850 Org: User:
Start: 11/30/15 End: 06/26/17 Due: 06/26/18

A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA Nephropathy

Phase: N/A Priority: Normal
NCT ID: NCT04014335 Org: User:
Start: 12/04/19 End: 04/11/24 Due: 04/11/25

HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT05127226 Org: User:
Start: 12/22/21 End: 03/31/29 Due: 03/31/30

A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera

Phase: N/A Priority: Normal
NCT ID: NCT05143957 Org: User:
Start: 12/30/21 End: 06/30/26 Due: 06/30/27

Mechanistic Study of ISIS ISIS-APOCIIIRX in Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT01647308 Org: User:
Start: 07/31/12 End: 03/31/14 Due: 03/31/15

A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously to Hypertensive Participants With Controlled Blood Pressure

Phase: N/A Priority: Normal
NCT ID: NCT03714776 Org: User:
Start: 01/03/19 End: 11/13/19 Due: 11/13/20

ISIS 14803-CS2, Treatment With ISIS 14803, Administered IV in Patients With Chronic Hepatitis C Virus Infections

Phase: N/A Priority: Normal
NCT ID: NCT00035945 Org: User:
Start: 10/01/01 End: 05/01/04 Due: 05/01/05

A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia

Phase: N/A Priority: Normal
NCT ID: NCT05610280 Org: User:
Start: 11/21/22 End: 06/30/25 Due: 06/30/26

Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Phase: N/A Priority: Normal
NCT ID: NCT03446144 Org: User:
Start: 03/16/18 End: 10/10/18 Due: 10/10/19

Safety, Tolerability, PK, and Pharmacodynamics(PD) of IONIS APOCIII-LRx in Healthy Volunteers With Elevated Triglycerides

Phase: N/A Priority: Normal
NCT ID: NCT02900027 Org: User:
Start: 09/30/16 End: 04/30/18 Due: 04/30/19

ATTR Expanded Access Program (EAP) by Ionis

Phase: N/A Priority: Normal
NCT ID: NCT03400098 Org: User:
Start: - End: - Due: -

Study to Evaluate the Effect of ISIS GCGRRx on Hepatic Lipid and Glycogen Content in Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT02824003 Org: User:
Start: 04/30/16 End: 05/22/17 Due: 05/22/18

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)

Phase: N/A Priority: Normal
NCT ID: NCT05130450 Org: User:
Start: 11/18/21 End: 02/29/28 Due: 02/28/29

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ionis AGT-LRx in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT03101878 Org: User:
Start: 04/05/17 End: 08/01/18 Due: 08/01/19

Safety, Tolerability and Efficacy of ISIS-GCCRRx in Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT01968265 Org: User:
Start: 10/31/13 End: 05/31/15 Due: 05/31/16

A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients With Alexander Disease (AxD)

Phase: N/A Priority: Normal
NCT ID: NCT04849741 Org: User:
Start: 06/01/21 End: 09/30/29 Due: 09/30/30

OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)

Phase: N/A Priority: Normal
NCT ID: NCT05139810 Org: User:
Start: 12/03/21 End: 11/09/23 Due: 11/09/24